Corcept Therapeutics Incorporated (CORT) News
Filter CORT News Items
CORT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CORT News Highlights
- CORT's 30 day story count now stands at 19.
- Over the past 23 days, the trend for CORT's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- BEAT, LINK and CERE are the most mentioned tickers in articles about CORT.
Latest CORT News From Around the Web
Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.
3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu CoinWhen it comes to high-flying cryptocurrencies, Shiba Inu (CRYPTO: SHIB) is among the most visible. Fueled by a frenzy of speculative buying late last year, the cheerful memes minted by the coin's community, known as the Shiba Army, are doubtlessly one of its enduring appeals. On the other hand, you probably haven't heard of Corcept Therapeutics (NASDAQ: CORT), a biotech company that's worth just over $2.6 billion. |
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff On Q4 2021 Results - Earnings Call TranscriptCorcept Therapeutics Incorporated (CORT) Q4 2021 Results Conference Call February 15, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants... |
Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks. |
Corcept Therapeutics (CORT) Q4 2021 Earnings Call TranscriptCORT earnings call for the period ending December 31, 2021. |
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues MissCorcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same. |
Corcept Therapeutics Incorporated 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Corcept Therapeutics Incorporated in conjunction with their 2021 Q4 earnings call.... |
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate UpdateMENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. |
Corcept Therapeutics (CORT) Q4 Earnings Beat EstimatesCorcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Corcept Therapeutics Q4 2021 Earnings PreviewCorcept Therapeutics (NASDAQ:CORT) is scheduled to announce Q4 earnings results on Tuesday, Feb. 15, after market close.The consensus EPS estimate is $0.35 |
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?With its stock down 13% over the past three months, it is easy to disregard Corcept Therapeutics (NASDAQ:CORT... |